Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions has completed the acquisition of a group of anthrax monoclonal antibodies from Avanir Pharmaceuticals, including Avanir's lead product candidate, AVP-21D9.
Subscribe to our email newsletter
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients with symptoms of anthrax disease following exposure to Bacillus anthracis.
In non-clinical studies, this candidate demonstrated an ability to protect animals challenged with a lethal dose of inhaled anthrax spores. AVP-21D9 is being developed with funding support from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, including a grant to establish a cGMP manufacturing process and to test efficacy in additional inhalation studies.
Fuad El-Hibri, chairman and CEO of Emergent BioSolutions, said: “The acquisition of Avanir’s monoclonal anthrax antibodies rounds out our anthrax countermeasure program nicely. This transaction reflects our ongoing commitment to develop a full portfolio of countermeasures to strengthen our country’s preparedness in the event of future anthrax attacks.”